ABIGAIL SCHELLHAMMER: Open Payments
NPI 1508239534 · LANSING, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,595 in 201 payments from 18 companies in 2025. Trend: 2023 $554 · 2024 $1,555 · 2025 $2,595
Food & beverage: $2,595
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $352 |
| Vanda Pharmaceuticals Inc. | 18 | $267 |
| Teva Pharmaceuticals USA, Inc. | 18 | $266 |
| ABBVIE INC. | 23 | $259 |
| Supernus Pharmaceuticals, Inc. | 35 | $254 |
| Otsuka America Pharmaceutical, Inc. | 18 | $232 |
| E.R. Squibb & Sons, L.L.C. | 18 | $226 |
| Corium, LLC | 11 | $155 |
| Neurocrine BioSciences, Inc. | 9 | $139 |
| Janssen Pharmaceuticals, Inc | 5 | $106 |
Products named: CAPLYTA, FANAPT, VRAYLAR, Qelbree, COBENFY, Azstarys, AUSTEDO XR, INGREZZA.
Industry payments across MI — which companies pay providers there.
